Objective: Loss of lean body mass with aging may contribute to falls and fractures. The objective of this analysis was to determine if taking postmenopausal hormone therapy (or HT: estrogen plus progestogen therapy or estrogen therapy alone) favorably affects age-related changes in lean body mass and if these changes partially account for decreased falls or fractures with HT.
W omen after menopause often experience a decrease in lean body mass, 1 an increase in body fat mass, and a shift to central or android fat distribution, 2 which may increase their risk for sarcopenia, diabetes, and cardiovascular diseases. These body composition changes are believed to be, at least in part, caused by a sudden decline in endogenous estrogen production at the time of menopause. Therefore, it has been hypothesized that menopausal hor-mone therapy (HT) may help counter these changes in body composition among postmenopausal women. 2<4 Most of the previous investigations in this area have been limited to observational studies and clinical trials, with small sample sizes or short intervention times. Techniques for assessing body composition have varied widely across the studies, and many findings have been based on anthropometric measurements, such as body mass index or hip and waist circumferences, as Disclaimer: The authors have no commercial, proprietary, or financial interest in the products or instruments described in this article.
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Recently, a subsample of the Women's Health Initiative (WHI) estrogen plus progestogen therapy (EPT) trial was used to investigate the affect of EPT on body composition. 5 This subsample included women who had body composition measurements at baseline and year 3 from the three WHI bone mineral density (BMD) centers. The findings from the subsample indicated that a 3-year EPT intervention significantly helped to maintain lean body mass and prevented the shift toward android fat distribution in postmenopausal women. The effect size of EPT on lean body mass was relatively small (G1 kg); however, we should expect that the beneficial treatment effect of estrogen alone from the WHI estrogen therapy alone (ET) trial on body composition to be at least as large as the findings from the WHI EPT trial, because previous studies have suggested that the magnitude of the impact of ET on body composition might be larger than that of EPT. 6 It has been reported that both EPT and ET interventions significantly reduced fracture risk among postmenopausal women. 7, 8 To understand the clinical implications of the beneficial effect of HT on lean body mass, we proposed to investigate whether the preserved lean body mass by HT contributed to the reduction in fracture risks among women assigned to hormone interventions in both the EPT and the ET trials. Most fractures occur because of a fall. Hence, we also tested whether the lean body mass effects of HT also influence fall risk.
We hypothesized that long-term use of postmenopausal HT (EPT, ET) would favorably affect age-related changes in lean body mass and that this favorable effect on lean body mass would contribute to a decrease in fractures.
METHODS

Study participants and procedures
Between 1993 and 1998, a total of 10,739 postmenopausal women with prior hysterectomy were recruited and enrolled in the WHI ET trial, and 16,608 postmenopausal women with an intact uterus were recruited and enrolled in the WHI EPT trial, at 40 WHI clinical centers in the United States. Both trials were randomized, double-blind, placebo-controlled trials. The inclusion criteria were similar between the EPT and ET trials, with the exception of hysterectomy among women in the ET trial; women were between 50 and 79 years and were postmenopausal. The protocol and consent forms were approved by the institutional review board at each site, and all participants provided written informed consent before participation. Details of the HT trials were described previously. 7, 8 The participants were stratified by age and block randomized by clinical center to either hormone treatment or placebo group for both the ET and the EPT trials; estrogen treatment in the ET trial was 0.625 mg/day conjugated equine estrogens daily (Premarin; Wyeth, Philadelphia, PA) and estrogen plus progesterone treatment in the EPT trial was 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxypro-gesterone acetate daily (Prempro; Wyeth). The washout period for prior HT use was 3 months before study initiation. Further design and participant details may be found in previously published articles. 9<11 The average (SD) length of participation in the ET trial was 7.7 (1.8) years and that of the EPT trial was 6.3 (1.5) years for those participating at the BMD clinical centers. Unblinding occurred in 2002 for the EPT trial and in 2004 for the ET trial.
Body composition by dual-energy x-ray absorptiometry (DXA) scans was assessed at three WHI BMD clinical centers (Pittsburgh, PA; Birmingham, AL; and Tucson-Phoenix, AZ) at baseline and every 3 years thereafter. Participants who completed the baseline, year 3, and year 6 DXA scans were included in this analysis. Diversity based on race/ethnicity was maximized in the WHI clinical centers where DXA measurements were conducted, and, therefore, in this substudy, the distribution differed from the WHI cohort at large.
Body composition assessment
Anthropometric measures included height, weight, and waist circumference. Weight was measured without shoes on a balance-beam scale to the nearest 0.1 kg. Height was measured by wall-mounted stadiometer to the nearest 0.1 cm. Body mass index (BMI) was calculated as weight (kg)/height (m 2 ). Waist circumference was measured by nonelastic tapes on all women at baseline and on a subset for years 3 (n = 1,622) and 6 (n = 1,429).
Body composition measurements were performed by DXA scans (QDR2000, 2000+, or 4500W; Hologic Inc, Bedford, MA). Whole-body DXA scans were used to determine both regional and total body compositions. Measurements included BMD, lean body mass (lean soft tissue mass), fat mass, percentage of fat mass, and lean body mass.
Standard WHI protocols were used for the positioning and analysis of DXA scans by radiology technicians, trained and certified by Hologic and the WHI Bone Density Coordinating Center at the University of California, San Francisco. Daily and weekly phantom scans were performed at each site for quality control. In addition, Hologic spine, hip, and block calibration phantoms were circulated and scanned across all WHI BMD sites and instruments. The WHI quality assurance program also included machine and technician performance monitoring by reviewing phantom scans, random sampling of scans, and review of scans with specific problems. The replacement of an older dual-energy x-ray absorptiometer with a newer model (QDR2000 to QDR4500W) was accounted for by linear regression equations developed from an independent sample of 50 women scanned with both DXA machines on the same day; adjustments for the total and regional body composition assessments were made accordingly, as previously published. 5 Falling and fracture assessments Falls were assessed by self-report semiannually. Fractures that occurred after study initiation were reported and confirmed for WHI BMD sites with a clinical chart review by trained physicians in the WHI. Total fractures were defined as all reported clinical fractures except those of the ribs, chest/ sternum, skull/face, fingers, toes, and cervical vertebrae. These fractures were confirmed by radiographic or operative reports. All hip fractures were confirmed by central adjudication and other fractures by local adjudication.
Assessment of covariates
Covariates of age, time since menopause, energy intake and other dietary variables, energy expenditure, ethnicity, smoking and alcohol habits, physical function, and prior HT use were assessed from baseline questionnaires. The last reported menstrual bleeding, time of bilateral oophorectomy, or initiation of menopausal HT was used to determine age at menopause and years of menopause. A validated food frequency questionnaire was used to assess energy intake, macronutrients, vitamins, and minerals. 12 To assess energy expenditure, the Compendium of Physical Activities by Ainsworth et al 13 was used to assign metabolic equivalent values to reported weekly recreational activities (ratio of work metabolic rate to resting metabolic rate by activity type). Physical function was assessed by the Medical Outcomes Study Scale, where the higher the score, the higher physical function indicated. 14 
Statistical analysis
Student's independent t tests for continuous variables and W 2 tests for categorical variables were used to compare characteristics, falls, fractures, and body composition between intervention groups for each trial at baseline, as well as for changes in body composition. Mixed models were used to test the average differences in lean mass and differences in the slope of change with time between the intervention and the placebo groups. Models further evaluating the contribution of lean body mass on falls and fractures were run with the intervention and control groups from each trial combined (ie, ET plus EPT vs ET placebo group combined with EPT placebo group to form active HT vs placebo) based on the similarity of baseline characteristics between HT and control groups in each trial, as well as the lack of HT effect on body composition at the primary endpoint of 6 years in this substudy. This collapse of groups to form active HT versus placebo yielded greater power and was soundly based on the lack of between-group differences at baseline and lack of difference between each HT group and its respective placebo for lean body mass at 6 years.
Cox proportional hazards survival models were used to investigate whether changes in lean body mass partially explained the treatment effect of HT on fracture risk by comparing the models with and without lean body mass. A similar logistic regression approach was used to examine whether HT was related to risk of falling and whether lean body mass is an explanatory factor in this relationship. In agreement with other large trials, a binary outcome variable of Bfaller[ was created with fallers defined as those with two or more falls per year 15, 16 because a history of two or more falls per year is a significant predictor of a recurrent faller 17 and a higher rate of falling is more highly associated with frailty-related fractures. 18 Based on prior evidence of a positive effect of HT on lean body mass at year 3 in the EPT trial, 5 logistic regression and Cox proportional hazards models were created using change in lean body mass data from baseline to year 3 to predict falls and fractures between years 3 and 6. Potential confounders such as baseline age, weight, ethnicity, geographic region of enrollment, number of years since menopause, HT use history, fracture history and broken bone at or after age 55 years, fall history, energy expenditure on recreational activities, physical function score, change in fat, and change in weight were evaluated by comparing unadjusted and adjusted associations of HT with outcomes; greater than 10% relative change between unadjusted and adjusted models was the a priori cut-point to identify a confounder. No potential confounders were identified; thus, covariates were not included in analyses. Because of unblinding of some participants before the year-6 DXA scan, analyses were run to compare those unblinded before year-6 DXA versus those that maintained blinded status at year 6; there was no significant effect of unblinding on fall or fracture analyses; therefore, intent-to-treat analyses were used including all participants.
Both intent-to-treat and sensitivity analyses were performed in comparisons between active HT (ET and EPT) and placebo groups to account for potential differences in the primary body composition outcomes based on medication compliance. Those that were 80% compliant or greater were compared with the total study cohort. All analyses were conducted using STATA software, version 10 (STATA Corp. College Station, TX). Significance was set for two-tailed tests at > = 0.05.
RESULTS
Descriptive characteristics of participants at baseline
Baseline descriptive characteristics for participants in the WHI ET and EPT trials at the WHI BMD sites are presented in Table 1 . Key demographic characteristics and habits were evaluated, in addition to physical function and fracture history. Within each trial, there were no differences between placebo and active HT intervention arms, with the exception of a trend toward differences in ethnic distribution between arms in the EPT trial, because of low sample sizes in some minority groups. Table 2 describes baseline body composition by anthropometry and DXA-derived tissue-specific measures, such as percent fat mass and lean body mass. All body composition measures were found to be similar between active HT and placebo groups for both the ET and EPT trials. Secondarily, although the mean age (63.3 T 7.4 y) and energy intake (1,699.0 T 863.1 kcal) were similar across all treatment and placebo groups at baseline, energy expenditure was higher overall in the EPT trial versus the ET trial (11.67 T 14.56 and 9.70 T 12.14 metabolic equivalents per week, respectively; P = 0.005), and the time since menopause in the ET trial was greater than that in the EPT trial (22.21 T 8.38 and 13.57 T 8.52, respectively; P G 0.0001). Similarly, physical functioning was not significantly different between intervention and control arms, but the percentage of women with physical function scores higher than 90 was higher in the EPT trial (28% ET vs 38% EPT, P G 0.001). BMI and waist circumference were also significantly lower in the EPT trial versus the ET trial (BMI: ET 29.93 T 5.57 kg/m 2 , EPT 28.22 T 5.45 kg/m 2 ; waist: ET 90.01 T 13.12 cm, EPT 85.85 T 12.64 cm; P G 0.0001), whereas prior hormone use was higher in the ET trial than in the EPT trial (P G 0.0001). In addition, baseline variables in completers versus dropouts were compared by t tests and demonstrated statistically significant differences between age at screening, time since menopause, weekly energy expenditure, physical functioning scores higher than 90, smoking status, supplemental vitamin D, and whole-body lean tissue mass (in kilograms; data not presented). However, these variables were not found to be confounders in further analyses. Figure 1 reflects the change in lean and fat mass (kg) during the first 3 years of each trial, with Fig. 2 spanning years 3 to 6. Table 2 also demonstrates the overall change in lean and fat mass between intervention groups from baseline to 6 years. Fat mass change was not significantly different between intervention and control groups at any of the time points examined. Lean body mass loss was significantly less in each of the active HT intervention arms of the ET and EPT trials compared with their respective placebo groups at 3 years ( Fig. 1 ). Between years 3 and 6, the relationship was reversed; the active ET group lost significantly more lean body mass than the respective placebo group (P G 0.05); there was a trend toward a greater loss of lean body mass among active EPT users versus the respective placebo group, as well ( Fig. 2 , P = 0.06). Thus, the effects over the full 6 years, presented in Table 2 , seem to be null; no significant differences between active and placebo groups were detected in either trial for change in lean body mass (in kilograms) at 6 years. Changes in appendicular lean body mass followed the same pattern at years 3 and 6 (data not presented). Overall, we saw a small decrease in lean body mass across all groups ranging from j0.29 to j0.50 kg at 6 years, with great variance; SDs ranged from 1.99 to 2.45 kg. The loss of lean body mass at 6 years on HT was less than lean body mass loss without HT, but the difference was not significant. When treatment arms were compared between trials, there was no significant difference between active ET and active EPT treatments for loss of lean body mass at 6 years. These findings were confirmed by mixed models (adjusted for age, weight, ethnicity, geographic region of enrollment, number of years since menopause, HT use before enrollment [ever], energy expenditure on recreational activities), where no significant effect of HT on lean body mass at 6 years was seen in either the ET or EPT trial (data not presented). These body composition findings for the overall group were in agreement with the findings in the subset of women taking at least 80% of their medication (data not presented); there were no treatment effects detected for HT regimen on either lean or fat mass compared with placebo at 6 years. Table 3 presents odds ratios for falls occurring between years 3 and 6 for active HT versus placebo. There was a nonsignificant reduction in annual fall risk (Q2 falls per year) between years 3 and 6 with HT use. These logistic regression models in the total sample did not show an independent effect of the early lean body mass change, baseline to 3 years, on decreased risk of falling between years 3 and 6. The relationship between HT and fall risk was not altered by change in lean body mass between baseline and year 3 or by baseline lean body mass. Upon exploration of HT trials separately, neither ET nor EPT alone significantly altered falls (Q2 falls/y) between years 3 and 6 compared with placebo in logistic regression models. The potential trend toward a reduction in falls for ET alone (ET: odds ratio, 0.48; 95% CI, 0.22-1.04; P = 0.06) was not explained by change in lean from baseline to year 3 or by baseline lean body mass. The relationship between EPT and falls was not significant (P = 0.46; data not presented). The median number of falls per person between years 3 and 6 differed between treatment and control by Wilcoxon's rank sum test for ET alone and HT combined (P = 0.005 and 0.03, respectively; see Table, Supplemental Digital Content 1, http://links.lww.com/MENO/A1); however, the contribution of lean body mass to these differences could not be evaluated by this nonparametric test. Table 4 presents hazard ratios for total fractures occurring between years 3 and 6, comparing active HT versus placebo. In this subanalysis of the WHI BMD sites, there was a nonsignificant reduction in fracture risk between years 3 and 6 with HT use. Change in lean body mass during the first 3 years of the trials was not independently associated with reduced risk of fractures between years 3 and 6, as evaluated by Cox proportional hazard models. The early change in lean body mass, baseline to year 3, did not alter the relationship between HT and fracture risk between years 3 and 6. Baseline lean mass did not alter the relationship between HT and fractures between years 3 and 6 either. When ET and EPT trials were explored separately, the results were not appreciably different from that of the HT combined analyses with respect to fractures.
Changes in body composition at 6 years
The relationship between HT, change in lean body mass, and falls or fractures
DISCUSSION
The WHI ET and EPT trials are the largest and longest randomized controlled trials to examine the affects of postmenopausal HT, providing an opportunity to evaluate the affects of HT on lean body mass and the lean body mass relationship to falls and fractures after administration of HT. Based on a prior evaluation of the WHI EPT trial (year 3), 5 the ongoing preservation of lean body mass via EPT was considered probable, and the affect of ET on lean body mass was hypothesized to match or exceed that of EPT at 6 years. 6 We were able to confirm that lean body mass loss was less with either ET or EPT at 3 years compared with placebo; however, despite plausible biological linkages and prior shortterm evidence, the early preservation of lean body mass was lost by 6 years, and there were no differences between placebo and HT treatment groups. Thus, there was a delay of lean body mass loss with HT, but the benefit did not persist long-term.
Others have also found short-term enhancement of lean body mass with HT. In the Bone Estrogen and Strength Training trial, postmenopausal women using and not using HT who were randomly assigned to the no-exercise group were followed during the intervention year for changes in body composition. Women in the no-exercise, no-HT group lost significant lean body mass, whereas women in the no-exercise, HT group preserved lean body mass and demonstrated a trend toward gain in lean body mass (P = 0.08) at 1 year. A similar study by Sipila et al 19 also found that lean body mass was enhanced by 1 year of HT compared with control without exercise. Sorensen et al 4 conducted a short-term crossover study of HT among postmenopausal women which indicated a role for HT in increasing lean body mass. These results from smaller trials support the early preservation of lean body mass noted in the WHI report of EPT 5 at year 3 and in ET at year 3 from this analysis.
In contrast, several other 2-to 3-year trials with various measures of lean body mass after HT in postmenopausal women have found no effect of HT. Sites et al 20 found no effect of EPT on lean body mass compared with placebo at 2 years. Kenny et al 21 found no change in lean body mass at 3 years with ultralow-dose ET. The Women's Health, Osteoporosis, Progestin, Estrogen trial, a randomized, double-blind, placebo-controlled trial of women (n = 749) randomized to various HT regimens (four doses of ET, three doses of EPT, plus one placebo group), found no differences between groups for DXA-derived changes in lean body mass at 2 years. 22 All groups experienced similar, small losses in lean body mass. Finally, Tanko et al 23 found no change in appendicular lean body mass with HT at 3 years and noted that the trend toward a decrease in appendicular lean body mass in HT groups compared with placebo between years 2 and 3 may suggest a catabolic rather than anabolic effect of HT over time.
Although not a focus of this article, upon evaluation of the WHI HT intervention cohorts, appendicular lean body mass followed the same pattern as overall lean body mass, that is, preservation at year 3, but no differences between treatment and control arms at 6 years, and thus is not in agreement with the findings of Tanko et al and does not support a catabolic affect of HT on lean body mass. In agreement with our findings, a 5-year randomized controlled trial of HT, the Danish Osteoporosis Prevention Study, found no significant difference between treatment and control for change in lean body mass at 5 years. 24 Importantly, the rapid loss of lean body mass seen by others during early menopausal years 1 was not evident in these cohorts, regardless of treatment arm. All groups within the WHI BMD sites, regardless of assignment to HT or placebo, lost 0.5 kg or less at 6 years, as opposed to 2 to 3 kg per year in the 3-year randomized placebo-controlled trial by Aloia et al. 1 Our 3-year results contrast with that of Aloia et al, in that we found that HT was associated with the preservation of lean body mass, but by year 6 of our analysis, there were no differences between the HT and placebo arms for change in lean body mass. Although the Danish Osteoporosis Prevention Study in younger women (45-58 y) also demonstrated minimal lean body mass loss at 5 years, 24 we may speculate that the relatively long time since menopause (13-22 y) among the women of the WHI HT trials included in the WHI BMD sites and the small degree of change in lean body mass overall during this window of time may have affected our ability to detect a long-term effect of HT on lean body mass. Data from women participating in the Third National Health and Nutrition Examination Survey evaluation of lean body mass by bioelectrical impedance support a general decline in the pace of lean body mass loss as menopause progresses if we compare by age groups spanning typical menopausal years. The prevalence of normal lean body mass decreased by 20% when comparing age groups 40-49 to 50-59 years; the prevalence of normal lean body mass declined by another 11% by ages 60 to 69 years and then remained level until 80+ years. 25 The average age of our cohorts at baseline was 63 years. Thus, it is also possible that if investigated earlier in the menopausal years, the affect of HT on lean body mass at 6 years may be more in line with our hypothesis of longer term preservation with HT administration.
In this analysis, we also evaluated the contribution of the early preservation of lean body mass with HT (baseline to year 3) to the risk of annual falls and the incidence of fracture in later years. We hypothesized that the reduction in fractures known to accompany HT 10,11 may be partially explained by the preservation of lean body mass and that lean body mass preservation may also contribute to reduced falls. These hypotheses were based on earlier work by Baumgartner et al 26 and Melton et al 27 demonstrating associations between critically low lean body mass, termed sarcopenia, and falls, and fractures. In the presence of HT, change in lean body mass has also been a predictor of BMD, which is related to fracture risk. 24 These hypotheses were primarily rejected by results from this analysis. We did not find a relationship between the preservation of lean body mass up to year 3 and subsequent annual falls and fractures between years 3 and 6.
In agreement with the findings of a large observation study, The Study of Osteoporotic Fractures, we found that postmenopausal HT use did not significantly reduce the risk of falling. 28 HT was associated with a nonsignificant risk reduction in both falls and fractures between years 3 and 6. However, there was a suggestion of decreased risk of total falls at 6 years with HT, which may occur by an unknown mechanism and is worthy of further investigation.
Although not significant in this subsample, the fracture risk reduction was within the range of the main WHI EPT 10 and ET trials. 11 However, these findings were not explained by early preservation of lean body mass via HT for falls or for fractures. The WHI Observational Study points toward other soft tissue changes in risk of falling and fractures; they recently reported that more obese women may be at greater risk of falling and site-specific fractures, 29 which was not evaluated in this substudy of the HT intervention arms of WHI. In this analysis, we found a nonsignificant 8% increase in risk of falling and 5% increase in total fractures with increased lean body mass, which may be an indication of increased overall body size and would support the recent WHI Observational Study results. When we evaluated the change in weight and change in body fat in the respective statistical models, there was no independent effect of weight or body fat on falls or total fractures, and the relationships between HT, lean body mass, and falls and fractures were not changed; however, sitespecific fractures were not evaluated.
The present analysis was focused on change in lean body mass, which was not predictive of falling and fractures, and other long-term trials relating HT-induced changes in lean body mass to risk of falling and fracture could not be located for comparison. However, there is evidence that exercise training can both improve muscle function and reduce risk of falling. 30 A recent meta-analysis suggested that HT may also improve strength, 31 which may lead to reduced risk of falling and subsequent fractures. Further research is needed to evaluate strength enhancement by HT and fall and fracture patterns over several years.
The randomized, placebo-controlled trial design, relatively large sample size, and lengthy duration (6 y) of the analysis are major strengths of this substudy of the WHI HT trials. This substudy is an important addition to the previously published 3-year analysis of EPT effects on body composition, 5 which included baseline and year 3 measurements only. Herein we were able to demonstrate that ET alone conferred similar lean body mass benefits at 3 years. This 6-year analysis also allowed us to examine trends in HT effects on lean body mass, and although it may be informative to examine even longer periods of HT treatment, the analysis was limited to the time period in which we had the greatest number of blinded participants in both the ET and EPT trials.
Importantly, the mean BMI and mean age in the subsample were representative of the entire WHI ET and EPT cohorts by intervention assignments at baseline. 10, 11 Although other base-line characteristics, such as ethnicity, varied slightly between the WHI cohorts at large and the WHI BMD sites, block randomization occurred by clinical center, such that we would expect the similar results if these analyses were repeated in the entire WHI cohort. In addition, this study was limited by the small number of fractures for specific sites, so the effects of lean body mass on fracture risk at hip, lumbar spine, and forearms could not be assessed separately. Our relatively small number of events (falls and fractures) was a limitation of our study, and future studies with larger sample sizes and longer follow-up may provide more insight into the relationship between lean mass, falls, and fractures because a greater number of events will be more probable. The use of DXAderived lean body mass to proxy skeletal muscle mass is also a limitation of this study. Although a good relationship between DXA-derived lean body mass and skeletal muscle mass measured on magnetic resonance imaging has already been reported, 32 whether DXA is sensitive enough to detect changes in lean body mass is unknown.
CONCLUSIONS
In conclusion, HT conferred an early benefit of preserved lean body mass in postmenopausal women, but longer term preservation of lean body mass did not endure. In addition, the early preservation of lean body mass in these cohorts did not predict risk of falling or fracture. There is some indication that HT may reduce the risk of falls, but further study will be needed to evaluate the threshold of postmenopausal lean body mass improvement, including strength changes, required to decrease risk or falls and fractures, with and without HT.
